

BIGFOOT BIOMEDICAL AND YPSOMED ANNOUNCE AGREEMENT

Ypsomed to Supply Bigfoot with Patient-Friendly Insulin Infusion Sets for Clinical Use

Milpitas, California, United States, and Burgdorf, Switzerland, October 24, 2017 – Bigfoot Biomedical and Ypsomed (SWX:YPSN) today announced that the companies have entered into an agreement under which Ypsomed will supply Bigfoot with a customized proprietary version of its Orbit[®] infusion sets as part of Bigfoot's investigational automated insulin pump-based solution for use in a pivotal trial.

With an intense focus on ease of use for people managing insulin-requiring diabetes, Bigfoot sought an infusion set that would work well with its proprietary connector cap and complement its developing device and software ecosystem designed to automatically and continuously optimize insulin delivery. "Ypsomed's Orbit[®] infusion set is thoughtfully designed," said Jeffrey Brewer, Bigfoot president and chief executive officer. "We're looking forward to incorporating a cannula and tubing that is flexible, reliable, and simple-to-operate into our clinical trial."

"Both Ypsomed and Bigfoot are devoted to developing solutions that make patients' lives easier. This agreement today is a reflection of our two companies' commitment to this shared goal" said Simon Michel, Ypsomed's chief executive officer.

The differentiating features of the Orbit[®] infusion set are its full 360° rotation, which provides freedom of movement for the wearer's convenience, as well as its simple insertion process and daily operation, which offer flexibility and comfort. The low-profile infusion set uses a heat-activated, semi-transparent adhesive patch that allows it to stay securely on the skin. The subcutaneous cannula is available in both soft and steel versions based on the user's preference.

In July 2017, Bigfoot announced a commercial agreement with Abbott to integrate Abbott's FreeStyle[®] Libre glucose sensing technology with Bigfoot's insulin delivery systems in the United States, a developing portfolio that includes a connected insulin pen-based system.

Bigfoot completed its first clinical trial of its investigational automated insulin delivery system in late 2016 and anticipates that a pivotal trial of the system, using Ypsomed's infusion set and Abbott's sensing technology, will begin in 2018 at clinical study sites across the United States.

About Bigfoot Biomedical, Inc.

Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes and, with its Loop and Inject services, seeks to change the paradigm of care for insulin-requiring diabetes by leveraging data, connectivity, automation, and machine learning to reduce the burden on people with insulin-requiring diabetes and maximize the leverage of health care providers. Learn more at bigfootbiomedical.com. Follow us on Twitter [@BigfootBiomed](https://twitter.com/BigfootBiomed) and [Facebook](https://www.facebook.com/BigfootBiomed).

About Ypsomed Group

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands, mylife[™] Diabetescare directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs around 400 employees.

Media Contacts:

Krysta Pellegrino
krysta@healthandcommerce.com
Melissa Lee
mlee@bigfootbiomedical.com
Thomas Kutt
Head of Investor Relations, Ypsomed
thomas.kutt@ypsomed.com